Common chemotherapeutic agent reduces resistance to virus therapy in brain tumor patients
Preclinical studies of oncolytic virus therapy in malignant glioma are promising; however, a potential problem with this approach is that the body’s own immune system can recognize the virus and clear the infection, resulting in reduced therapeutic effects. For this study, researchers used a mouse model with an intact immune system to mimic what would occur in humans to determine how the immune system clears the oncolytic virus. They found that the area surrounding malignant gliomas has a high number of immune cells called microglial cells and macrophages…